This site is intended for health professionals only
Today at EuroPCR, Medtronic Inc released four-year data from the ENDEAVOR II clinical trial that reinforces the long-term safety and durable efficacy of the company’s Endeavor Zotarolimus-Eluting Coronary Stent System for the treatment of coronary artery disease.
“As the duration of follow-up in ENDEAVOR II grows, so too does our confidence in the enduring safety and effectiveness of the Endeavor stent,” said Dr Jean Fajadet of the Clinique Pasteur Unité de Cardiologie Interventionnelle in Tolouse, France, who presented the data at the late-breaking clinical trials session.
“The durability of this device’s performance is remarkable based on these four-year results, which show low rates of late adverse events.”
The newly released data indicate that the Endeavor stent offers durable efficacy out to four years of follow-up, with no new events requiring target lesion revascularization (TLR) between years three and four.
They also reinforce the long-term safety record of the Endeavor stent, which was associated with no new episodes of stent thrombosis over the same period.
Compared with Medtronic’s Driver bare-metal stent (the control in ENDEAVOR II), these trial results show a lower rate of target vessel failure (TVF) for patients treated with the Endeavor stent – due largely to a diminished rate of target vessel revascularization (TVR). TVF is a composite of TVR, myocardial infarction and cardiac death.